Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles
暂无分享,去创建一个
Yoshihiro Yamanishi | Masaaki Kotera | Hiroaki Iwata | Ryusuke Sawada | Sayaka Mizutani | Yoshihiro Yamanishi | Ryusuke Sawada | Masaaki Kotera | Sayaka Mizutani | Hiroaki Iwata
[1] Kyoung Mii Park,et al. CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.
[2] Chih-Jen Lin,et al. LIBLINEAR: A Library for Large Linear Classification , 2008, J. Mach. Learn. Res..
[3] W. Bonadio,et al. Safe and effective method for application of tetracaine, adrenaline, and cocaine to oral lacerations. , 1996, Annals of emergency medicine.
[4] Robert B. Russell,et al. SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..
[5] R Michael Siatkowski,et al. Ocular rosacea in childhood. , 2004, American journal of ophthalmology.
[6] E. Marcotte,et al. A flaw in the typical evaluation scheme for pair-input computational predictions , 2012, Nature Methods.
[7] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[8] D Hare,et al. The Orange Book: the Food and Drug Administration's advice on therapeutic equivalence. , 1990, American pharmacy.
[9] Yang Zhang,et al. Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[10] Yasuo Tabei,et al. Identification of chemogenomic features from drug–target interaction networks using interpretable classifiers , 2012, Bioinform..
[11] Lei Huang,et al. DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..
[12] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[13] Mark Goadrich,et al. The relationship between Precision-Recall and ROC curves , 2006, ICML.
[14] R. Sharan,et al. INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.
[15] Ravi Iyengar,et al. Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.
[16] Yasuo Tabei,et al. Inferring protein domains associated with drug side effects based on drug-target interaction network , 2013, BMC Systems Biology.
[17] Michael Shannon,et al. Drug Interactions—A Review , 2005 .
[18] Xing-Ming Zhao,et al. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..
[19] Susumu Goto,et al. Network-Based Analysis and Characterization of Adverse Drug-Drug Interactions , 2011, J. Chem. Inf. Model..
[20] S. Vilar,et al. Detection of Drug-Drug Interactions by Modeling Interaction Profile Fingerprints , 2013, PloS one.
[21] M. Relling,et al. Moving towards individualized medicine with pharmacogenomics , 2004, Nature.
[22] W. E. Woods,et al. Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. , 1996, Equine veterinary journal.
[23] Mark J Mannis,et al. Efficacy and Safety of Recurrent Pterygium Surgery Using Human Processed Pericardium , 2002, Cornea.
[24] Yoshihiro Yamanishi,et al. Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.
[25] Julian Blagg,et al. Structure–Activity Relationships for In vitro and In vivo Toxicity , 2006 .
[26] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[27] D. Bojanic,et al. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.
[28] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[29] Li Mao,et al. Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells , 2022 .
[30] Carol Friedman,et al. Drug-drug interaction through molecular structure similarity analysis , 2012, J. Am. Medical Informatics Assoc..
[31] J. Irwin,et al. Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.
[32] Yoshihiro Yamanishi,et al. KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..
[33] A S Hossain,et al. Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the treatment of acute severe asthma. , 2013, Mymensingh medical journal : MMJ.
[34] Gilles Marcou,et al. Computational chemogenomics: Is it more than inductive transfer? , 2014, Journal of Computer-Aided Molecular Design.
[35] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[36] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[37] Xia Li,et al. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of randomized controlled trials , 2013, Journal of the Neurological Sciences.
[38] S. Ray,et al. Bicarbonate Plus Epinephrine Shortens the Onset and Prolongs the Duration of Sciatic Block Using Chloroprocaine Followed by Bupivacaine in Sprague-Dawley Rats , 2008, Regional Anesthesia & Pain Medicine.
[39] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[40] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[41] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[42] U. R. Chowdhury,et al. Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models , 2008, Clinical Cancer Research.
[43] Damian Szklarczyk,et al. STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..
[44] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[45] Jürgen Bajorath,et al. Classification of Compounds with Distinct or Overlapping Multi-Target Activities and Diverse Molecular Mechanisms Using Emerging Chemical Patterns , 2013, J. Chem. Inf. Model..
[46] George Hripcsak,et al. Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.
[47] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[48] Igor I. Baskin,et al. Predicting Ligand Binding Modes from Neural Networks Trained on Protein-Ligand Interaction Fingerprints , 2013, J. Chem. Inf. Model..
[49] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..